Compare BBGI & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBGI | CTXR |
|---|---|---|
| Founded | 1961 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 13.4M |
| IPO Year | 1999 | 2010 |
| Metric | BBGI | CTXR |
|---|---|---|
| Price | $5.67 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.0K | ★ 295.0K |
| Earning Date | 11-13-2026 | 12-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ 48.01 | N/A |
| Revenue | ★ $232,179,463.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.47 | $104.18 |
| P/E Ratio | $0.12 | ★ N/A |
| Revenue Growth | ★ 69.89 | N/A |
| 52 Week Low | $3.14 | $0.37 |
| 52 Week High | $29.30 | $1.54 |
| Indicator | BBGI | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 25.65 | 53.63 |
| Support Level | $3.50 | $0.52 |
| Resistance Level | $24.70 | $0.63 |
| Average True Range (ATR) | 0.63 | 0.07 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 14.44 | 53.36 |
Beasley Broadcast Group Inc is a multi-platform media company whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA; Augusta, GA; Boston, MA; Charlotte, NC; Detroit, MI; Fayetteville, NC; Fort Myers-Naples, FL; Las Vegas, NV; Middlesex, NJ; Monmouth, NJ; Morristown, NJ; Philadelphia, PA; Tampa-Saint Petersburg, FL; and Wilmington, DE. The company operates in two segments: Audio, which generates the maximum revenue, and Digital.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.